Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Strokappe, Nika ^a   Szynol, Agnieszka ^a   Aasa Chapman, Marlèn ^b   Gorlani, Andrea ^a   Quigley, Anna ^b   Hulsik, David Lutje ^c   Chen, Lei ^d   Weiss, Robin ^b   de Haard, Hans ^a   Verrips, Theo ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIV GRENOBLE ALPES   (France)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY B12; UNCLASSIFIED DRUG; VARIABLE DOMAIN OF THE HEAVY CHAIN OF THE HEAVY CHAIN ANTIBODY; VIRUS ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; ARTIODACTYLA; BINDING COMPETITION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; LLAMA; MOLECULAR STABILITY; NONHUMAN; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS STRAIN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; CLASSIFICATION; COMPLEMENTARITY DETERMINING REGION; CROSS REACTION; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; IN VITRO STUDY; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SERODIAGNOSIS; SITE DIRECTED MUTAGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL); LAMA GLAMA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BINDING, COMPETITIVE; CAMELIDS, NEW WORLD; COMPLEMENTARITY DETERMINING REGIONS; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84863238167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033298     Document Type: Article

References (74)

1. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77 (19): 10557-10565.
2. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (7129): 732-737 10.1038/nature05580.
3. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455 (7209): 109-113 10.1038/nature07159.
4. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, et al. (2011) An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 6 (3): e18207 10.1371/journal.pone.0018207.
5. Herrera C, Klasse PJ, Michael E, Kake S, Barnes K, et al. (2005) The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338 (1): 154-172 10.1016/j.virol.2005.05.002.
6. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80 (5): 2515-2528 10.1128/JVI.80.5.2515-2528.2006.
7. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11 (6): 615-622 10.1038/nm1244.
8. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, et al. (2008) In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers. J Virol 82 (3): 1591-1599 10.1128/JVI.01792-07.
9. Huber M, von Wyl V, Ammann CG, Kuster H, Stiegler G, et al. (2008) Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 82 (8): 3834-3842 10.1128/JVI.02569-07.
10. Burton DR, Stanfield RL, Wilson IA, (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102 (42): 14943-14948 10.1073/pnas.0505126102.
11. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat Med 15 (8): 866-870 10.1038/nm.1949.
12. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 (23): 13232-13252 10.1128/JVI.78.23.13232-13252.2004.
13. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L, (2006) Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 3 (7): e255 10.1371/journal.pmed.0030255.
14. Peeters M, (2001) The genetic variability of HIV-1 and its implications. Transfus Clin Biol 8 (3): 222-225.
15. Xu W, Smith-Franklin BA, Li PL, Wood C, He J, et al. (2001) Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 4 (2): 55-61.
16. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107 (25): 11483-11488 10.1073/pnas.1004600107.
17. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 326 (5950): 285-289 10.1126/science.1178746.
18. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5 (1): e8805 10.1371/journal.pone.0008805.
19. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 10.1126/science.1187659.
20. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (6049): 1633-1637 10.1126/science.1207227.
21. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 (5956): 1123-1127 10.1126/science.1175868.
22. Chen W, Dimitrov DS, (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4 (2): 112-117 10.1097/COH.0b013e328322f95e.
23. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363 (6428): 446-448 10.1038/363446a0.
24. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, et al. (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11 (3): 500-515 10.1110/ps.34602.
25. Muyldermans S, (2001) Single domain camel antibodies: Current status. J Biotechnol 74 (4): 277-302.
26. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S, (1997) Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol 34 (16-17): 1121-1131.
27. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84 (16): 8098-8110 10.1128/JVI.00966-10.
28. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, et al. (2010) Targeting trojan horse leukocytes for HIV prevention. AIDS 24 (2): 163-187 10.1097/QAD.0b013e32833424c8.
29. Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, et al. (2005) Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 71 (1): 442-450 10.1128/AEM.71.1.442-450.2005.
30. Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, et al. (2001) Thermal unfolding of a llama antibody fragment: A two-state reversible process. Biochemistry 40 (1): 74-83.
31. Saerens D, Conrath K, Govaert J, Muyldermans S, (2008) Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol 377 (2): 478-488 10.1016/j.jmb.2008.01.022.
32. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, et al. (1999) Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431 (1): 37-46.
33. Hultberg A, Tremblay DM, de Haard H, Verrips T, Moineau S, et al. (2007) Lactobacillli expressing llama VHH fragments neutralise lactococcus phages. BMC Biotechnol 7: 58 10.1186/1472-6750-7-58.
34. Thomassen YE, Verkleij AJ, Boonstra J, Verrips CT, (2005) Specific production rate of VHH antibody fragments by saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation. J Biotechnol 118 (3): 270-277 10.1016/j.jbiotec.2005.05.010.
35. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, et al. (2008) Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82 (24): 12069-12081 10.1128/JVI.01379-08.
36. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 (16): 10108-10125 10.1128/JVI.79.16.10108-10125.2005.
37. Gao F, Yue L, Craig S, Thornton CL, Robertson DL, et al. (1994) Genetic variation of HIV type 1 in four world health organization-sponsored vaccine evaluation sites: Generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO network for HIV isolation and characterization. AIDS Res Hum Retroviruses 10 (11): 1359-1368.
38. McKeating JA, Bennett J, Zolla-Pazner S, Schutten M, Ashelford S, et al. (1993) Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J Virol 67 (9): 5216-5225.
39. Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, et al. (2006) Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation. Biochim Biophys Acta 1764 (8): 1307-1319 10.1016/j.bbapap.2006.05.011.
40. Daley LP, Gagliardo LF, Duffy MS, Smith MC, Appleton JA, (2005) Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids. Clin Diagn Lab Immunol 12 (3): 380-386 10.1128/CDLI.12.3.380-386.2005.
41. Chomczynski P, Sacchi N, (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: Twenty-something years on. Nat Protoc 1 (2): 581-585 10.1038/nprot.2006.83.
42. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, et al. (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56 (3): 303-317 10.1007/s00262-006-0180-4.
43. De Haard HJ, Bezemer S, Ledeboer AM, Muller WH, Boender PJ, et al. (2005) Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol 187 (13): 4531-4541 10.1128/JB.187.13.4531-4541.2005.
44. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, et al. (1991) By-passing immunization. human antibodies from V-gene libraries displayed on phage. J Mol Biol 222 (3): 581-597.
45. Bracci L, Pini A, Lozzi L, Lelli B, Battestin P, et al. (2001) Mimicking the nicotinic receptor binding site by a single chain fv selected by competitive panning from a synthetic phage library. J Neurochem 78 (1): 24-31.
46. Meulemans EV, Slobbe R, Wasterval P, Ramaekers FC, van Eys GJ, (1994) Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody. J Mol Biol 244 (4): 353-360 10.1006/jmbi.1994.1735.
47. Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJ, (2003) Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta 1624 (1-3): 21-28.
48. Lutje Hulsik D, (2009) Improving properties of llama heavy chain antibodies using in silico analysis. Gildeprint BV ISBN:978-90-393-5023-2.
49. Achour I, Cavelier P, Tichit M, Bouchier C, Lafaye P, et al. (2008) Tetrameric and homodimeric camelid IgGs originate from the same IgH locus. J Immunol 181 (3): 2001-2009.
50. Vriend G, (1990) Parameter relation rows: A query system for protein structure function relationships. Protein Eng 4 (2): 221-223.
51. Ledeboer AM, Bezemer S, de Hiaard JJ, Schaffers IM, Verrips CT, et al. (2002) Preventing phage lysis of lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. J Dairy Sci 85 (6): 1376-1382.
52. Kuroki M, (1996) A simple solid-phase competition assay with labeled antigen. Methods Mol Biol 66: 47-53 10.1385/0-89603-375-9:47.
53. Soutullo A, Verwimp V, Riveros M, Pauli R, Tonarelli G, (2001) Design and validation of an ELISA for equine infectious anemia (EIA) diagnosis using synthetic peptides. Vet Microbiol 79 (2): 111-121.
54. Wright PF, Nilsson E, Van Rooij EM, Lelenta M, Jeggo MH, (1993) Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. Rev Sci Tech 12 (2): 435-450.
55. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12.11 10.1002/0471142735.im1211s64.
56. Rock EP, Sibbald PR, Davis MM, Chien YH, (1994) CDR3 length in antigen-specific immune receptors. J Exp Med 179 (1): 323-328.
57. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, et al. (2003) Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 77 (1): 642-658.
58. Tzartos SJ, (1996) Epitope mapping by antibody competition. methodology and evaluation of the validity of the technique. Methods Mol Biol 66: 55-66 10.1385/0-89603-375-9:55.
59. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74 (18): 8358-8367.
60. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46 (6): 1896-1905.
61. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, et al. (1999) A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7 (4): 361-370.
62. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, et al. (1996) Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 3 (9): 803-811.
63. Bures R, Morris L, Williamson C, Ramjee G, Deers M, et al. (2002) Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from south africa. J Virol 76 (5): 2233-2244.
64. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern africa. J Virol 80 (23): 11776-11790 10.1128/JVI.01730-06.
65. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 (5996): 1168-1174 10.1126/science.1193748.
66. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97 (16): 9026-9031.
67. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, et al. (2002) Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76 (19): 9888-9899.
68. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (6686): 648-659 10.1038/31405.
69. Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, et al. (2005) Structure of the fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol 79 (20): 13060-13069 10.1128/JVI.79.20.13060-13069.2005.
70. Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, et al. (2010) Crystal structure of the neutralizing llama V(HH) D7 and its mode of HIV-1 gp120 interaction. PLoS One 5 (5): e10482 10.1371/journal.pone.0010482.
71. Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, et al. (2011) Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 6 (4): e17665 10.1371/journal.pone.0017665.
72. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA, (2010) sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 7: 11 10.1186/1742-4690-7-11.
73. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ, (2004) HIV-1 cell to cell transfer across an env-induced, actin-dependent synapse. J Exp Med 199 (2): 283-293 10.1084/jem.20030648.
74. Gorlani A, Brouwers J, McConville C, van der Bijl P, Malcolm K, et al. (2011) Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res Hum Retroviruses 10.1089/aid.2011.0133.